{"id":"NCT01028053","sponsor":"GE Healthcare","briefTitle":"Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease","officialTitle":"A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2009-12-09","resultsPosted":"2014-09-11","lastUpdate":"2014-09-11"},"enrollment":365,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Mild Cognitive Impairment","Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Flutemetamol (18F) Injection","otherNames":["Flutemetamol","18F"]}],"arms":[{"label":"Flutemetamol (18F) Injection","type":"EXPERIMENTAL"}],"summary":"This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.","primaryOutcome":{"measure":"Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.","timeFrame":"Up to 36 months post flutemetamol administration","effectByArm":[{"arm":"Hazard Ratio","deltaMin":3.418,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["35351181"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":232},"commonTop":[]}}